修订欧盟药品立法:它是否会促进药物的重新用途?
Mirre Scholte1, Sabine E Grimm2, Bianca Pauly3
1Department of Clinical Epidemiology & Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, the Netherlands; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands; Departments of IQ Health and Radiology, Radboudumc, Nijmegen, the Netherlands; REPO4EU consortium.
Drug discovery today
|January 5, 2025
概括
药物再利用为未满足的需求提供低成本的治疗方法. 拟议的欧盟立法面临学术和非营利性使用的障碍,需要加强支持和更明确的政策以实现更广泛的采用.
科学领域:
- 制药政策 制药政策
- 药物的发现和开发.
背景情况:
- 非专利药物再利用为针对未满足医疗需求的负担得起的治疗提供了可行的途径.
- 欧盟 (EU) 已经出台了新的制药立法,其中规定了药物的重新用途.
研究的目的:
- 分析拟议的欧盟制药立法,涉及药物的重新用途.
- 确定学术和非营利性实体在利用这些新的重定向激励措施时所面临的障碍.
- 提出建议,加强欧盟内的药物重用倡议.
主要方法:
- 审查拟议的欧盟制药立法.
- 对学术和非营利性利益相关者发现的障碍的分析.
- 制定政策提升方面的建议.
主要成果:
- 拟议的欧盟立法对学术和非营利性药物重新利用利益相关者提出了挑战.
- 关键障碍包括对监管流程的有限知识,药物监管要求和数据保护限制.
- 这些障碍阻碍了立法的潜力.
结论:
- 欧盟立法需要加强,以有效支持非营利性药物重用者.
- 额外的科学,监管和卫生技术评估 (HTA) 支持至关重要.
- 建立公平的数据保护期限和定价政策对于成功实施至关重要.
- 需要一个全面的欧盟药物重用战略,以促进各种类型的药物的重用.
相关概念视频
Drug Control Governance: Regulatory Bodies and Their Impact
139
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
139
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Drug Biotransformation: Overview
2.3K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.3K
Prodrugs
2.4K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.4K
Pharmacovigilance
771
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
771
Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K


